Compare two dialysis membranes to adjust heparin use
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study compares two dialysis membranes while using a reduced “weaning” plan for the blood thinner heparin during hemodialysis. It aims to see which membrane works better and safely during routine chronic dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old
- You have been on regular hemodialysis for at least 3 months, about 3 times per week
- You currently take blood thinning medicine during dialysis (heparin: either UFH or LMWH)
- You are covered by French Social Security and have signed consent to join
- You must NOT be using hemodiafiltration (HDF) or dialysis via a catheter on screening day
- Your blood counts, infection/inflammation level, and dialysis setup must meet safety limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two methods for removing waste products from the blood in people who need dialysis. It aims to see whether one method works better or is safer during extra-renal (outside the body) blood purification.
This study compares three types of dialysis filters to see which works best at removing waste from your blood and improving your health outcomes. If you receive regular hemodialysis at a clinic, this trial may help doctors understand which filter type is most effective for you.
This trial tests three experimental antibodies given to people with end-stage kidney disease who are on hemodialysis. It aims to see if these drugs are safe and how they affect blood clotting in this group.
This study tests whether dialysis can be done safely without using heparin (a blood thinner) in people with end-stage kidney disease. If successful, it could reduce the need for blood-thinning medications and their associated risks.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This study compares two blood-thinning drugs (nafamostat and heparin) that are given during dialysis for kidney failure caused by sepsis. The goal is to see which drug is safer and helps keep the dialysis filter working better.
Hear when a new Renal Insufficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.